Nanoparticles Targeted against Cryptococcal Pneumonia by Interactions between Chitosan and Its Peptide Ligand

Tang, Yixuan; Wu, Shuang; Lin, Jiaqi; Cheng, Liao‐Ping; Zhou, Jing; Xie, Jing; Huang, Kexin; Wang, Xiaoyou; Ye, Yu; Chen, Zhangbao; Liao, Guojian; Li, Chong

doi:10.1021/acs.nanolett.8b02229

Cited by 68 publications

(42 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prepared nanodrug can be administered orally and has targeting property. The results showed that the nanodrug could significantly kill Cryptococcus neoformans in lung infection foci, thus improving the survival rate of infected mice [178]. Studies have shown that biodegradable ITZ-loaded d-a-tocopheryl PEG 1000 succinate-b-poly(e-caprolactoneran-glycolide) NPs (designed as ITZ-loaded tripolyphosphate (TPP) NPs) can improve the antifungal efficacy.…”

Section: Fungus Infectionsmentioning

confidence: 99%

Recent applications and strategies in nanotechnology for lung diseases

et al. 2021

View full text Add to dashboard Cite

Lung diseases, including COVID-19 and lung cancers, is a huge threat to human health. However, for the treatment and diagnosis of various lung diseases, such as pneumonia, asthma, cancer, and pulmonary tuberculosis, are becoming increasingly challenging. Currently, several types of treatments and/or diagnostic methods are used to treat lung diseases; however, the occurrence of adverse reactions to chemotherapy, drug-resistant bacteria, side effects that can be significantly toxic, and poor drug delivery necessitates the development of more promising treatments. Nanotechnology, as an emerging technology, has been extensively studied in medicine. Several studies have shown that nano-delivery systems can significantly enhance the targeting of drug delivery. When compared to traditional delivery methods, several nanoparticle delivery strategies are used to improve the detection methods and drug treatment efficacy. Transporting nanoparticles to the lungs, loading appropriate therapeutic drugs, and the incorporation of intelligent functions to overcome various lung barriers have broad prospects as they can aid in locating target tissues and can enhance the therapeutic effect while minimizing systemic side effects. In addition, as a new and highly contagious respiratory infection disease, COVID-19 is spreading worldwide. However, there is no specific drug for COVID-19. Clinical trials are being conducted in several countries to develop antiviral drugs or vaccines. In recent years, nanotechnology has provided a feasible platform for improving the diagnosis and treatment of diseases, nanotechnology-based strategies may have broad prospects in the diagnosis and treatment of COVID-19. This article reviews the latest developments in nanotechnology drug delivery strategies in the lungs in recent years and studies the clinical application value of nanomedicine in the drug delivery strategy pertaining to the lung.

show abstract

Section: Fungus Infectionsmentioning

confidence: 99%

Recent applications and strategies in nanotechnology for lung diseases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Targeted delivery at the disease site is currently of great interest in the biomedical field. From the recent works on biosensors, Surface Plasmon Resonance (SPR) has been widely used to monitor the biomolecular interactions that can detect the interaction between functionalized nanoparticles with a specific ligand [ 35 , 36 ]. To investigate the binding affinity between A10-PBM-NP and PSMA, we employed covalent coupling on sensor ship-based SPR.…”

Section: Resultsmentioning

confidence: 99%

Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer

Singh

Gordetsky

Bae

et al. 2020

Cells

View full text Add to dashboard Cite

An abnormality in hedgehog (Hh) signaling has been implicated in the progression of prostate cancer (PCa) to a more aggressive and therapy-resistant disease. Our assessments of human PCa tissues have shown an overexpression of the Hh pathway molecules, glioma-associated oncogene homolog 1 (GLI-1), and sonic hedgehog (SHH). The effect of the natural compound thymoquinone (TQ) in controlling the expression of Hh signaling molecules in PCa was investigated in this study. We generated planetary ball-milled nanoparticles (PBM-NPs) made with a natural polysaccharide, containing TQ, and coated with an RNA aptamer, A10, which binds to prostate-specific membrane antigen (PSMA). We prepared docetaxel-resistant C4-2B-R and LNCaP-R cells with a high expression of Hh, showing the integration of drug resistance and Hh signaling. Compared to free TQ, A10-TQ-PBM-NPs were more effective in controlling the Hh pathway. Our findings reveal an effective treatment strategy to inhibit the Hh signaling pathway, thereby suppressing PCa progression.

show abstract

“…Notably, free chitosan (C-CP-NPs/ITZ) did not influence the efficiency of drug incorporation and it did not impact drug release. Both CP-NPs/ITZ and C-CP-NPs/ITZ prolonged the survival of mice with pulmonary cryptococcosis, although C-CP-NPs/ITZ was more effective (Tang et al, 2018 ).…”

Section: Current Scenario Of Nanotechnology In the Treatment And Vaccmentioning

confidence: 99%

Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

Kischkel

Rossi

Santos

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Treatment modalities for systemic mycoses are still limited. Currently, the main antifungal therapeutics include polyenes, azoles, and echinocandins. However, even in the setting of appropriate administration of antifungals, mortality rates remain unacceptably high. Moreover, antifungal therapy is expensive, treatment periods can range from weeks to years, and toxicity is also a serious concern. In recent years, the increased number of immunocompromised individuals has contributed to the high global incidence of systemic fungal infections. Given the high morbidity and mortality rates, the complexity of treatment strategies, drug toxicity, and the worldwide burden of disease, there is a need for new and efficient therapeutic means to combat invasive mycoses. One promising avenue that is actively being pursued is nanotechnology, to develop new antifungal therapies and efficient vaccines, since it allows for a targeted delivery of drugs and antigens, which can reduce toxicity and treatment costs. The goal of this review is to discuss studies using nanoparticles to develop new therapeutic options, including vaccination methods, to combat systemic mycoses caused by Candida sp., Cryptococcus sp., Paracoccidioides sp., Histoplasma sp., Coccidioides sp., and Aspergillus sp., in addition to providing important information on the use of different types of nanoparticles, nanocarriers and their corresponding mechanisms of action.

show abstract

Nanoparticles Targeted against Cryptococcal Pneumonia by Interactions between Chitosan and Its Peptide Ligand

Cited by 68 publications

References 37 publications

Recent applications and strategies in nanotechnology for lung diseases

Recent applications and strategies in nanotechnology for lung diseases

Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer

Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

Contact Info

Product

Resources

About